Study using Parsortix in head and neck cancer | 28-Sep-2022 | 07:00 | RNS |
New poster presented at ASCP Meeting | 13-Sep-2022 | 07:00 | RNS |
Novel assay predicts malignancy in pelvic mass | 12-Sep-2022 | 07:30 | RNS |
Notice of Interim Results and Webcast | 01-Sep-2022 | 07:00 | RNS |
Novel insight into metastasis in NSCLC patients | 28-Jul-2022 | 07:00 | RNS |
Holding(s) in Company | 20-Jul-2022 | 14:33 | RNS |
NEW STUDY OF PARSORTIX SYSTEM IN NSCLC | 20-Jul-2022 | 07:00 | RNS |
Director/PDMR Shareholding | 19-Jul-2022 | 10:00 | RNS |
Results of Capital Raise | 15-Jul-2022 | 07:00 | RNS |
Retail Offer via PrimaryBid | 14-Jul-2022 | 17:24 | RNS |
Proposed Placing and Retail Offer | 14-Jul-2022 | 17:23 | RNS |
Issue of Equity | 08-Jul-2022 | 17:30 | RNS |
Result of 2022 Annual General Meeting | 29-Jun-2022 | 16:35 | RNS |
Spread of breast cancer accelerates during sleep | 27-Jun-2022 | 07:00 | RNS |
Issue of Equity | 23-Jun-2022 | 18:24 | RNS |
Currency | UK Pounds |
Share Price | 13.63p |
Change Today | -0.38p |
% Change | -2.68 % |
52 Week High | 31.35 |
52 Week Low | 9.24 |
Volume | 807,041 |
Shares Issued | 319.08m |
Market Cap | £43.47m |
RiskGrade | 312 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
Strong Buy | 1 |
Buy | 0 |
Neutral | 0 |
Sell | 0 |
Strong Sell | 0 |
Total | 1 |
No dividends found |
Time | Volume / Share Price |
14:22 | 34 @ 13.78p |
13:54 | 35,500 @ 13.85p |
13:52 | 5,000 @ 13.87p |
13:12 | 996 @ 13.88p |
13:12 | 1,000 @ 13.88p |
CEO | Andrew D Newland |
Finance Director | Ian F Griffiths |
Chair | Jan Groen |
You are here: research